HNN3.0
Register
Register
Register

Pharmahungary Group

Company (SME)

www.pharmahungary.com/Szeged, Budapest, Hungary

About

We are looking to join grant consortium that would benefit from our core R&D expertise:

providing wide range of innovative and cost-effective preclinical pharmacology R&D services focusing on but not limited to cardiovascular (infarction, heart failure, stroke, sepsis, arrhythmias, etc) metabolic diseases (diabetes, dyslipidemia, atherosclerosis, obesity, uremia, etc), renal, and inflammation indications with strong scientific support

clinical R&D services focusing on full management of clinical trials with Medical Devices, Advanced Therapeutic Medicinal Products, Investigator Initiated Trials, and clinical trials that need strong regulatory & scientific support with e.g. sensitive patient population

to manage internal R&D projects to develop new technologies for out-licensing and co-development in the fields of diagnosis and therapy of cardiovascular and metabolic disease

Representatives

Business Development Director

Pharmahungary Group

Marketplace (1)

  • Project cooperation

    miRNA discovery & development bioinformatics tools

    Based on our proprietary bioinformatics tool, (mirnatarget.com) we have developed a novel platform that is able to predict mRNA targets of differentially expressed miRNAs, as well as design custom miRNA sequences for various diseases.

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
    Author

    Business Development Director at Pharmahungary Group

    Budapest, Hungary